Century Therapeutics financials
$1.65−1.20%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 |
|---|---|---|---|---|---|
| Revenue | $109.2M | $6.6M | $2.2M | $5.2M | — |
| Gross profit | $109.2M | $6.6M | $2.2M | $5.2M | — |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | — |
| Operating income | -$17.3M | -$138.1M | -$146.5M | -$133.8M | -$94.9M |
| Net income | -$9.6M | -$126.6M | -$136.7M | -$130.9M | -$95.8M |
| Net margin | −8.8% | −1920.9% | −6115.1% | −2518.4% | — |
| Diluted EPS | $-0.14 | $-1.61 | $-2.30 | $-2.27 | $-2.96 |
| EBITDA | $2.6M | -$120.5M | -$117.1M | -$125.4M | -$91.1M |
| Operating cash flow | -$103.9M | -$110.1M | -$88.3M | $14.1M | -$89.0M |
| Free cash flow | -$104.7M | -$110.3M | -$102.1M | -$16.6M | -$134.0M |
| Diluted shares | 86.6M | 78.6M | 59.3M | 57.8M | 32.4M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|
| Cash & equivalents | $61.9M | $58.4M | $47.3M | $84.3M | $56.4M |
| Short-term investments | $55.3M | $130.9M | $125.4M | $231.2M | $166.4M |
| Total debt | $0.00 | $0.00 | $0.00 | $10.2M | $9.9M |
| Total assets | $223.7M | $353.2M | $360.7M | $486.5M | $437.4M |
| Total liabilities | $64.8M | $191.9M | $175.9M | $183.8M | $41.1M |
| Shareholders' equity | $158.9M | $161.4M | $184.8M | $302.7M | $396.2M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology